Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer"
DOI: 10.1002/cncr.33033
Abstract: BACKGROUND CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long-term clinical benefits of nivolumab versus… read more here.
Keywords: patients advanced; long term; everolimus; checkmate 025 ... See more keywords
Pharmacokinetic Drug-Drug Interaction With Coadministration of Cannabidiol and Everolimus in a Phase 1 Healthy Volunteer Trial.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical pharmacology in drug development"
DOI: 10.1002/cpdd.1262
Abstract: When highly purified cannabidiol (CBD; Epidiolex) and the mammalian target of rapamycin inhibitor everolimus are used concomitantly in the treatment of tuberous sclerosis complex, there is evidence of a pharmacokinetic (PK) interaction, leading to increased… read more here.
Keywords: interaction; everolimus; cannabidiol; concentration ... See more keywords
Everolimus Inhibits Growth of Gemcitabine‐Resistant Pancreatic Cancer Cells via Induction of Caspase‐Dependent Apoptosis and G2/M Arrest
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Cellular Biochemistry"
DOI: 10.1002/jcb.25921
Abstract: Pancreatic cancer is the fourth leading cause of cancer‐related death in the United States. While Gemcitabine‐based chemotherapy is the first‐line treatment for locally advanced pancreatic cancer, its resistance is a large obstacle in the field.… read more here.
Keywords: everolimus; gemcitabine; resistant pancreatic; pancreatic cancer ... See more keywords
Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12)
Sign Up to like & getrecommendations! Published in 2017 at "Metabolomics"
DOI: 10.1007/s11306-017-1236-5
Abstract: IntroductionEverolimus selectively inhibits mammalian target of rapamycin complex 1 (mTORC1) and exerts an antineoplastic effect. Metabolic disturbance has emerged as a common and unique side effect of everolimus.ObjectivesWe used targeted metabolomic analysis to investigate the… read more here.
Keywords: muscle cells; pathway; everolimus; effect everolimus ... See more keywords
Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer letters"
DOI: 10.1016/j.canlet.2016.10.015
Abstract: Mammalian target of rapamycin (mTOR) inhibitor, everolimus, provides benefit for metastatic hormone receptor positive breast cancer after failure of the endocrine therapy. The present report highlights Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2 (DYRK2) as… read more here.
Keywords: hormone receptor; everolimus; receptor positive; mtor ... See more keywords
Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2018.07.013
Abstract: Metastatic breast cancer (MBC) is the leading cause of cancer-related morbidity and mortality among women worldwide. Endocrine therapy is the standard of care for the most common subtype of MBC, hormone-receptor positive (HR+), human epidermal… read more here.
Keywords: everolimus; breast cancer; metastatic breast; everolimus based ... See more keywords
The mTOR inhibitor everolimus attenuates tacrolimus-induced renal interstitial fibrosis in rats.
Sign Up to like & getrecommendations! Published in 2021 at "Life sciences"
DOI: 10.1016/j.lfs.2021.120150
Abstract: AIMS Tacrolimus-a widely used immunosuppressant to prevent allograft rejection after organ transplantation-is nephrotoxic, increasing the risk of kidney injury accompanied by kidney fibrosis. The mammalian target of rapamycin (mTOR) inhibitor, everolimus, is an immunosuppressant used… read more here.
Keywords: everolimus; fibrosis; induced kidney; kidney fibrosis ... See more keywords
Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure‐effect relationship
Sign Up to like & getrecommendations! Published in 2017 at "Pharmacological Research"
DOI: 10.1016/j.phrs.2017.04.029
Abstract: Introduction: Therapeutic drug monitoring (TDM) of everolimus is not performed in oncology and no trough level (C0) target has been yet defined. The aim of this study was to determine everolimus C0 target for toxicity… read more here.
Keywords: everolimus; therapeutic drug; cancer; drug monitoring ... See more keywords
Spontaneous Chylous Ascites After Liver Transplantation Secondary to Everolimus: A Case Report.
Sign Up to like & getrecommendations! Published in 2020 at "Transplantation proceedings"
DOI: 10.1016/j.transproceed.2019.10.036
Abstract: Chylous ascites (CA) is an uncommon entity with several etiologies. Only a few cases of CA have been reported as a complication after liver transplantation (LT). Most of these cases occurred within 1 month after… read more here.
Keywords: everolimus; case; report; liver transplantation ... See more keywords
Everolimus depletes plaque macrophages, abolishes intraplaque neovascularization and improves survival in mice with advanced atherosclerosis.
Sign Up to like & getrecommendations! Published in 2019 at "Vascular pharmacology"
DOI: 10.1016/j.vph.2018.12.004
Abstract: BACKGROUND AND AIMS Inhibition of the mechanistic target of rapamycin (mTOR) is a promising approach to halt atherogenesis in different animal models. This study evaluated whether the mTOR inhibitor everolimus can stabilize pre-existing plaques, prevent… read more here.
Keywords: advanced atherosclerosis; intraplaque neovascularization; everolimus; plaque macrophages ... See more keywords
Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Investigation"
DOI: 10.1080/07357907.2017.1344697
Abstract: ABSTRACT A meta-analysis of randomized controlled trials (RCTs) was performed to examine the risk of everolimus discontinuation due to related and unrelated adverse events (AE) in cancer patients. Fifteen RCTs were analyzed that compared everolimus… read more here.
Keywords: due related; everolimus; related unrelated; discontinuation ... See more keywords